New York-based pharmaceutical giant Bristol-Myers Squibb announced Thursday it will buy US biotech firm Celgene in a massive $74 billion cash and stock deal to create a specialized biopharma company.
New York-based pharmaceutical giant Bristol-Myers Squibb announced Thursday it will buy US biotech firm Celgene in a massive $74 billion cash and stock deal to create a specialized biopharma company.